ACCESS ULTRASENSITIVE HGH CALIBRATOR, MODEL 33585

K061282 · Beckman Coulter, Inc. · JIT · Jun 2, 2006 · Clinical Chemistry

Device Facts

• Record ID: K061282
• Device Name: ACCESS ULTRASENSITIVE HGH CALIBRATOR, MODEL 33585
• Applicant: Beckman Coulter, Inc.
• Product Code: JIT · Clinical Chemistry
• Decision Date: Jun 2, 2006
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 862.1150
• Device Class: Class 2

Indications for Use

The Beckman Coulter Access Ultrasensitive hGH Calibrators are intended for use with the Access Immunoassay Systems for the calibration of the Access Ultrasensitive hGH assay.

Device Story

Access Ultrasensitive hGH Calibrators; used with Access Immunoassay Systems; calibrates hGH assay for quantitative measurement of human growth hormone in serum/plasma; modification involves re-standardization from WHO pituitary 80/505 IS to recombinant WHO 98/574 2nd IS; fundamental scientific technology remains unchanged; used in clinical laboratory settings by trained personnel; output provides calibration curves for assay performance; ensures accurate hGH quantification for clinical decision-making.

Clinical Evidence

Bench testing only. Verification and validation activities performed per design control procedures; results met predetermined acceptance criteria.

Technological Characteristics

Lyophilized calibrators containing hGH. Traceable to WHO 98/574 standard. Used with Access Immunoassay Systems (one-step immunoenzymatic sandwich assay). No changes to materials, functionality, or stability compared to predicate.

Indications for Use

Indicated for the calibration of the Access Ultrasensitive hGH assay on Access Immunoassay Systems for the quantitative determination of human growth hormone (hGH) in human serum and plasma.

Regulatory Classification

Identification

A calibrator is a device intended for medical purposes for use in a test system to establish points of reference that are used in the determination of values in the measurement of substances in human specimens. (See also § 862.2 in this part.)

Special Controls

*Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Predicate Devices

• Beckman Coulter Access Ultrasensitive hGH Calibrators (k003098)

Submission Summary (Full Text)

{0}

SPECIAL 510(k): Device Modification

ODE Review Memorandum (Decision Making Document is Attached)

To: THE FILE

RE: DOCUMENT NUMBER k061282

This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable (delete/add items as necessary):

1. The name and 510(k) number of the SUBMITTER'S previously cleared device. (For a preamendments device, a statement to this effect has been provided.) Beckman Coulter Access Ultrasensitive hGH Calibrators, k003098
2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).
3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.

This change was for: re-standardization of the device from the WHO pituitary 80/505 international standard (IS) to the recombinant WHO 98/574 2nd IS.

4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, physical characteristics, and traceability.
5. A Design Control Activities Summary which includes:

a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis The sponsor performed Failure Mode Effects Analysis (FMEA).
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied
c) A declaration of conformity with design controls. The declaration of conformity should include:

i) A statement signed by the individual responsible, that, as required by the risk analysis, all verification and validation activities were performed by the designated individual(s) and the results demonstrated that the predetermined acceptance criteria were met, and
ii) A statement signed by the individual responsible, that the manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review.

6. A Truthful and Accurate Statement, a 510(k) Summary or Statement and the Indications for Use Enclosure (and Class III Summary for Class III devices).

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.